TPST Tempest Therapeutics, Inc. Insider Trading

CEO Angel Matthew buys 231,482 shares of TPST at $2.16 ($500.0K) with stock at $1.74, down -70.6% from 52-week high.

Angel Matthew, as CEO, acquired 231,482 shares at $2.16 on 2026-03-24, representing an immediate $0.42-per-share loss relative to today's $1.74 price. The company is materially stressed: net income was $-3.5M in the latest quarter, annual revenue contracted -54.8% year-over-year, and the stock has declined -27.5% over the past 30 days after already falling -70.6% from its 52-week high of $5.92. This was the CEO's first purchase ever (zero pre-transaction holdings), so this represents a new personal equity stake at a price point that is now underwater. The transaction signals either renewed conviction at depressed levels or a necessity to retain talent through equity compensation, but the fundamental deterioration—declining revenue, persistent losses, and recent price weakness—frames this acquisition in the context of a company in distress rather than emerging opportunity.

TPST CEO Brady Stephen R buys 35,000 shares at $2.11 on 2024-07-03; 2 other insiders also bought within 14 days

Brady Stephen R, President and CEO, purchased 35,000 shares at $2.11, expanding his holdings by 307.7% to 46,376 shares post-transaction. This acquisition is part of a cluster pattern, with 2 other insiders also buying within the past 14 days. The transaction occurred at a significant distance from the 52-week high of $63.50 (currently -78.5% below that peak), against a backdrop of severe operational deterioration: the company generated $55,000.00 in latest quarterly revenue while posting a net loss of $-7,904,000.00, with annual revenue contraction of -54.8% and persistent unprofitability. The stock has declined -32.5% over 30 days and -45.7% over 90 days, establishing a steep downtrend at the time of purchase.

CMO bought 4,672 shares at $2.13; coordinated with 2 other insiders in 14-day cluster as stock fell 78.4% from 52-week high.

Whiting Samuel, Chief Medical Officer of Tempest Therapeutics, purchased 4,672 shares at $2.13 on 2024-07-02, nearly doubling his holdings from 4,901 to 9,573 shares. This transaction is part of a cluster pattern with 2 other insiders also buying within the past 14 days, suggesting coordinated capital deployment during a period of significant market stress. The stock has declined 78.4% from its 52-week high of $63.50 and fallen 35.0% over the past 30 days, while the company remains unprofitable with a net loss of $7,904,000.00 in the latest fiscal year and trailing revenue declining 54.8% year-over-year. The multiple concurrent purchases by insiders at dramatically depressed valuations warrant close scrutiny of whether this represents a genuine turning point or a capitulation-level buying event.

TPST corporate controller buys 7,500 shares at $2.16 amid 78.3% decline from 52-week high and -54.8% revenue contraction.

Justin Trojanowski, Corporate Controller at Tempest Therapeutics, purchased 7,500 shares at $2.16 on 2024-06-28, expanding his holdings by 51.1% to 22,168 shares post-transaction. This is noteworthy given the company's steep operational deterioration: full-year net income was negative (latest quarterly net loss $-7.9M), annual revenue contracted -54.8%, and the stock has fallen -78.3% from its $63.50 52-week high and declined -36.1% over the prior 30 days. The purchase at $2.16 represents an open-market acquisition by a finance officer at a deeply depressed valuation coinciding with severe business decline. Investors should closely monitor whether this reflects Trojanowski's personal assessment of intrinsic value or signals confidence in a stabilization plan, as well as track subsequent company disclosures and insider activity given the magnitude of operational contraction.